Sosei Group
Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing their platform technologies - GPCR structure-based drug design platform technology, peptide platform technologies and nanotechnology - they have established a product pipeline with first/best in class potential. Through development and commercialization partnerships they have already delivered three medicines to the market (two COPD bronchodilators and an emergency contraceptive), which generate significant and stable revenue streams that enable further growth.
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms. Its technology helps transform the therapy landscape of cancer and other severe diseases that enable doctors and physicians to cure diseases and develop medicines that restore normal function to patients' cells. The company was founded in 2008 and is headquartered in London, England.
JITSUBO aims to be a Peptide Lowest Cost Producer by continuously improving core technologies by incorporating all the latest technologies. JITSUBO company name is derived from "Chiba Jitsubo-san", a family business of Kazuhiro Chiba, a science and technology adviser and co-founder. Chiba Minorusan is a rare medicine that has been contributing to the health of people for over 500 years as a herbal medicine for women. The company named 'JITSUBO' from the desire to provide products that are useful for people's health through peptide drugs for a long time. We aim to be such a great mother-like company that continues to bring the results of technological innovation to the value of superior peptide drugs and continue to produce them in society.
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.
Arakis Limited is focuses on discovery and development of inflammatory diseases and oncology adjunctive therapy. The company's research capability specializes in the cytokine and receptor mediated mechanisms of disease. The company identifies, develops, and commercializes product opportunities based upon new clinical uses for known drugs or known drug templates, as well as termed performance enhanced medicines.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.